Search
Search Results
##search.searchResults.foundPlural##
-
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
3293PDF: 645Suppl. Files: 303HTML: 277 -
AGING WITH THALASSEMIA AND SICKLE CELL DISEASE: A GERONTOLOGICAL MODEL OF ACCELERATED MULTIMORBIDITY AND FUNCTION-CENTERED CARE BEYOND MIDLIFE Thalassemia and Sickle Cell Diseases: Effect of Aging
518PDF: 565Suppl. Files: 68HTML: 159 -
-
QUALITY OF LIFE IN PATIENTS WITH THALASSEMIA MAJOR AND INTERMEDIA IN KERMAN-IRAN (I.R.)
1742PDF: 804HTML: 2394Cover Letter: 210 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3156PDF: 1653HTML: 366 -
THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA in TDT
196PDF: 189HTML: 49 -
CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
4378PDF: 1566HTML: 470 -
-
A SEROPREVALENCE OF HBV, HCV AND HIV-1 AND CORRELATION WITH MOLECULAR MARKERS AMONG MULTI-TRANSFUSED THALASSEMIA PATIENTS IN WESTERN INDIA Incidence of serology & molecular of HIV, HBV and HCV in thalassemia patients
1462PDF: 786HTML: 541 -
END-OF-LIFE CARE IN SICKLE CELL DISEASE AND TRASFUSION DEPENDEND-β-THALASSEMIA: CLINICAL, PSYCHOLOGICAL, AND ETHICAL CONSIDERATION Challenges in Supportive Care, Equity, and Compassion at End of Life
1216PDF: 861Html: 198 -
-
A MULTICENTER ICET-A SURVEY ON ADHERENCE TO ANNUAL ORAL GLUCOSE TOLERANCE TEST (OGTT) SCREENING IN TRANSFUSION-DEPENDENT THALASSEMIA (TDT) PATIENTS - THE EXPERT CLINICIANS’ OPINION ON FACTORS INFLUENCING THE ADHERENCE AND ON ALTERNATIVE STRATEGIES FOR ADHERENCE OPTIMIZATION Survey on adherence to annual OGTT in thalassemia
2996PDF: 1386HTML: 169 -
High Prevalence of Antiphospholipid Antibodies in Children with Non-Transfusion Dependent Thalassemia and Possible Correlations with Microparticles Antiphospholipid Antibodies and Thalassemia in children
1072PDF: 642HTML: 315 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2503PDF: 1638HTML: 703 -
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3771PDF: 1338HTML: 2167Fig.1: 236Fig. 2: 230 -
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2810PDF: 864HTML: 15025Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 339 -
GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS
5506PDF: 1070HTML: 478TABLE: 209FIGURES: 280 -
Concordance Rate of Fasting Plasma Glucose (PG) and 2-hour PG post Oral Glucose Tolerance Test (OGTT) in Patients with new diagnosis of Thalassemia-Related Diabetes Mellitus (Th-RDM):Implications for Clinical Practice OGTT concordance rate in thalassemia major
785PDF: 594Html: 138 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
4043PDF: 1178HTML: 468 -
-
CAN WE PREDICT INCIPIENT DIABETES MELLITUS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (β-TDT) REFERRED WITH A HISTORY OF PREDIABETES? Risk factors for incipient diabetes in thalassemia
1166PDF: 1396HTML: 173 -
PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?
3003PDF: 1012HTML: 2118Cover letter: 198 -
EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT Sinopharm Vaccination in Iranian Patients with Hemoglobinopathies
1771PDF: 766HTML: 239 -
LIVER IRON CONTENT IN INDIVIDUALS WITH LIVER IRON CONTENT IN INDIVIDUALS WITH Β-THALASSEMIA TRAIT AND HYPERFERRITINEMIA: ROLE OF METABOLIC ALTERATIONS, HFE GENOTYPES, AND CIRRHOSIS.: ROLE OF METABOLIC ALTERATIONS, HFE GENOTYPES, AND CIRRHOSIS. Β-THALASSEMIA TRAIT AND HYPERFERRITINEMIA
265PDF: 302Suppl. Files: 29HTML: 39







